“This product is a breakthrough because of its proven results to improve overall health. It’s like the discovery of a new vitamin – it’s unique, affordable and easy, prompting an increase in sales worldwide.”
– Jolyon Burton
President and Head of Investment Banking, Bloom Burton & Co.
News & Media
Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2023
Ottawa, ON /Business Wire/ March 16, 2023/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and
Avivagen Reports Fiscal Year 2022 Financial Results and Strategic Initiatives to Accelerate Growth
New approvals for sales in multiple countries Raised more than $8.5 million in equity and debt financing Revenues of approximately
Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta™ Product Published in Peer-Reviewed Journal
Publication showcases the cumulative understanding to-date of Avivagen’s product from both a scientific and real world application perspective Product’s value
Avivagen is developing and commercializing products
that promote health in animals and humans.
Avivagen offers its commercial partners scientifically backed, evidence-based products which are in high demand from multiple channels including veterinarians, farmers and producers, pet owners and retailers.
Avivagen maintains the highest manufacturing standards and is a proud member of the NASC, a self-regulating body, which protects and enhances the integrity of the animal health product industry.
Avivagen is actively collaborating with companies in Canada, the United States, the Philippines, Korea, Vietnam, and Thailand, and we are seeking more relationships internationally.
